Product review on MAbs (alemtuzumab and ocrelizumab) for the treatment of multiple sclerosis

• Main Authors: Tereza Gabelić (Author), Barbara Barun (Author), Ivan Adamec (Author), Magdalena Krbot Skorić (Author), Mario Habek (Author)
• Format: Book
• Published: Taylor & Francis Group, 2021-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Traditionally, the management of active relapsing remitting MS was based on the, so-called, maintenance therapy, which is characterized by continuous treatment with particular disease modifying therapy (DMT), and a return of disease activity when the drug is discontinued. Another approach is charact...